Gie Groupe Hospitalier Paris Saint-Joseph/Vinci

The Respiratory Tract Diseases portfolio at Gie Groupe Hospitalier Paris Saint-Joseph/Vinci focuses on improving outcomes for patients after lung transplantation and those with severe pulmonary vascular disorders.

• Bronchiolitis Obliterans Syndrome
• Inoperable Chronic Thromboembolic Pulmonary Hypertension
• Lung Transplant Rejection
• Chronic Lung Allograft Dysfunction

Ongoing studies evaluate novel anti‑fibrotic agents and targeted therapies to preserve lung function and reduce the risk of graft failure.

The Cardiovascular Diseases investigations encompass surgical and minimally invasive procedures aimed at reducing cardiac complications and enhancing recovery.

• Conventional Cardiac Surgery (CABG, Aortic Replacement)
• Transcatheter Aortic Valve Implantation for Aortic Stenosis
• Isolated Tricuspid Valve Surgery for Severe Regurgitation
• Acute Myocarditis in Adults and Children
• Peripheral Arterial Disease with Intermittent Claudication

Trials assess antiplatelet strategies, pre‑operative cardioprotective drugs, and anti‑inflammatory regimens to lower postoperative events and improve vascular health.

Research in Immune System Diseases seeks to modulate abnormal inflammatory responses that threaten heart and lung tissue.

• Pediatric Acute Myocarditis
• Anakinra for Myocardial Inflammation
• Immunomodulatory Therapy after Lung Transplant

By testing cytokine inhibitors and tailored steroid protocols, investigators aim to restore normal immune balance and protect organ function.

The Neoplasms program concentrates on targeted treatment for a molecularly defined subgroup of lung cancer patients.

• RET Fusion‑Positive Non‑Small Cell Lung Cancer
• Evaluation of Selpercatinib Efficacy

Study outcomes will determine whether precision therapy can extend survival and delay disease progression in this rare oncologic population.

Clinical work in Pathological Conditions, Signs and Symptoms addresses measurable health indicators that guide therapeutic decisions.

• Composite Clinical Event Endpoints after Cardiac Procedures
• Walking Capacity Improvement in Intermittent Claudication
• Prevention of Post‑operative Atrial Fibrillation

These studies use functional tests and event tracking to evaluate how new interventions affect daily living and reduce complication rates.

Investigations of Circulatory and Respiratory Physiological Phenomena aim to quantify the impact of therapies on organ performance metrics.

• Pulmonary Vascular Resistance in CTEPH Patients
• Forced Expiratory Volume (FEV1) in Lung Allograft Dysfunction
• Cardiac Output Preservation in Tricuspid Valve Surgery

By linking physiological measurements to clinical outcomes, researchers hope to refine dosing strategies and improve patient prognosis.